238 related articles for article (PubMed ID: 25602962)
1. BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients.
Laroche-Clary A; Chaire V; Le Morvan V; Neuville A; Bertucci F; Salas S; Sanfilippo R; Pourquier P; Italiano A
Br J Cancer; 2015 Feb; 112(4):688-92. PubMed ID: 25602962
[TBL] [Abstract][Full Text] [Related]
2. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Italiano A; Laurand A; Laroche A; Casali P; Sanfilippo R; Le Cesne A; Judson I; Blay JY; Ray-Coquard I; Bui B; Coindre JM; Nieto A; Tercero JC; Jimeno J; Robert J; Pourquier P
Cancer; 2011 Aug; 117(15):3445-56. PubMed ID: 21287534
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Simpson EL; Rafia R; Stevenson MD; Papaioannou D
Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
[TBL] [Abstract][Full Text] [Related]
5. The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS).
Ploner F; Lamm W; Schur S; Eisterer W; Kühr T; Lindorfer A; Tinchon C; Köstler WJ; Szkandera J; Brodowicz T
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1337-42. PubMed ID: 23666164
[TBL] [Abstract][Full Text] [Related]
6. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
[TBL] [Abstract][Full Text] [Related]
7. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
Schöffski P; Taron M; Jimeno J; Grosso F; Sanfilipio R; Casali PG; Le Cesne A; Jones RL; Blay JY; Poveda A; Maki RG; Nieto A; Tercero JC; Rosell R
Eur J Cancer; 2011 May; 47(7):1006-12. PubMed ID: 21376569
[TBL] [Abstract][Full Text] [Related]
8. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
[TBL] [Abstract][Full Text] [Related]
9. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.
Vincenzi B; Stumbo L; Maltese G; Cerbone L; Spalato Ceruso M; Badalamenti G; Santini D; Tonini G; Frezza AM; De Lisi D; Silletta M
Sci Rep; 2015 Aug; 5():12077. PubMed ID: 26235506
[TBL] [Abstract][Full Text] [Related]
10. Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
Le Cesne A; Ray-Coquard I; Duffaud F; Chevreau C; Penel N; Bui Nguyen B; Piperno-Neumann S; Delcambre C; Rios M; Chaigneau L; Le Maignan C; Guillemet C; Bertucci F; Bompas E; Linassier C; Olivier T; Kurtz JE; Even C; Cousin P; Yves Blay J;
Eur J Cancer; 2015 Apr; 51(6):742-50. PubMed ID: 25727882
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin in patients with metastatic soft tissue sarcoma: a retrospective single center analysis.
Schur S; Lamm W; Köstler WJ; Hoetzenecker K; Nemecek E; Schwameis K; Klepetko W; Windhager R; Brodowicz T
Anticancer Drugs; 2013 Aug; 24(7):725-30. PubMed ID: 23728219
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
Fayette J; Boyle H; Chabaud S; Favier B; Engel C; Cassier P; Thiesse P; Méeus P; Sunyach MP; Vaz G; Ray-Coquard I; Ranchère D; Decouvelaere AV; Alberti L; Pérol D; Blay JY
Anticancer Drugs; 2010 Jan; 21(1):113-9. PubMed ID: 19887935
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
18. Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword.
Reichardt P
Future Oncol; 2015; 11(11 Suppl):1. PubMed ID: 26043309
[No Abstract] [Full Text] [Related]
19. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N
Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694
[TBL] [Abstract][Full Text] [Related]
20. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]